Key facts
- This page summarizes Eric Patzer's Form 4 filing for Aridis Pharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 19 Sep 2023, 16:05.
Eric Patzer - 18 Sep 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc.
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- N/A
- Reported as of
- 18 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2023, 16:05:24 UTC
- Prior SEC filing
- 15 Jun 2023
- Next SEC filing
- 28 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Patzer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Patzer filed Form 4 for Aridis Pharmaceuticals, Inc. on 19 Sep 2023.
Change
- Previous filing in this sequence was filed on 15 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARDS
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +10%
- Price
- $0.000000
- Shares after
- 161,862
- Date
- 18 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $0.0800
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
50% of the options vest on the date of grant and 1,250 vest on a monthly basis thereafter for six months.